MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, commented on the decision issued today by the European Court of Justice decision in the matter of Oliver Brüstle v Greenpeace. The Company believes that it will have minimal impact on ACT’s commercial efforts.
